A randomized, phase 3, open-label study of nivolumab versus temozolomide (TMZ) in combination with radiotherapy (RT) in adult patients (pts) with newly diagnosed, O-6-methylguanine DNA methyltransferase (MGMT)-unmethylated glioblastoma (GBM): CheckMate-498.-Reference-Cited by-同舟云学术

A randomized, phase 3, open-label study of nivolumab versus temozolomide (TMZ) in combination with radiotherapy (RT) in adult patients (pts) with newly diagnosed, O-6-methylguanine DNA methyltransferase (MGMT)-unmethylated glioblastoma (GBM): CheckMate-498.

Published:2016-05-20 Issue:15_suppl Volume:34 Page:TPS2079-TPS2079
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Sampson John H.¹,Omuro Antonio Marcilio Padula²,Preusser Matthias³,Lim Michael⁴,Butowski Nicholas A.⁵,Cloughesy Timothy Francis⁶,Strauss Lewis C.⁷,Latek Robert Raymond⁷,Paliwal Prashni⁷,Weller Michael⁸,Reardon David A.⁹

Affiliation:

1. Duke University Medical Center, Durham, NC;

2. Memorial Sloan Kettering Cancer Center, New York, NY;

3. Medical University of Vienna, Vienna, Austria;

4. The Johns Hopkins Hospital, Baltimore, MD;

5. University of California, San Francisco, San Francisco, CA;

6. University of California, Los Angeles, Los Angeles, CA;

7. Bristol-Myers Squibb, Princeton, NJ;

8. University Hospital Zurich, Zurich, Switzerland;

9. Dana-Farber Cancer Institute and Harvard University School of Medicine, Boston, MA;

Publisher

American Society of Clinical Oncology (ASCO)